LifeVantage Corporation

LifeVantage Corporation Earnings Recaps

LFVN Consumer Staples 3 recaps
Next earnings: November 9, 2026 (estimated) · full calendar
Q4 2026 Aug 29, 2026

LifeVantage shares fell 1.5% after earnings. Revenue declined 23.1%, while the new CEO said the company would not provide formal guidance as he assesses the business and develops a growth strategy, leaving the near-term outlook unclear.

Key takeaways
  • Fiscal Q4 revenue was $42.4 million, down 23.1% from $55.1 million a year earlier.
  • Management attributed the decline to fewer orders from active accounts and lower average order size, citing macroeconomic pressure and lower MindBody GLP-1 System sales against a higher year-ago comparison; LoveBiome sales partially offset the decline.
  • CEO Terrence Moorehead, who joined only a few weeks ago, identified brand positioning, the consumer proposition, and operational excellence and profitability as early priorities.
  • Moorehead said LifeVantage would not provide formal guidance while management assesses the business and develops a growth strategy.
  • The CEO cited historically near-80% gross margins as an opportunity, but the call excerpt provided no updated margin results.
Full recap
Q3 2026 May 8, 2026

LifeVantage shares fell 8.6% after Q3 fiscal 2026 results as investors reacted negatively to guidance concerns and signs of deceleration in key sales metrics, overshadowing the strategic initiatives management highlighted.

Key takeaways
  • Despite management's emphasis on new programs and digital investments, the company signaled a cautious outlook reflecting slower than expected top-line growth.
  • Momentum within the consultant community remains a key focus, but recent sales trends indicate deceleration in this critical segment.
  • Although e-commerce platform upgrades are underway, these investments weigh on near-term margin expansion and results.
  • The balance sheet remains strong with no debt and ample cash reserves, providing financial flexibility amid operational challenges.
  • Management’s commentary emphasized long-term growth initiatives, yet failed to offset investor concerns about near-term performance headwinds.
Full recap
Q2 2026 Feb 5, 2026

LifeVantage reported a notable decline in revenue this quarter due to increased competition in the GLP-1 market, despite progress in product diversification and integration from the LoveBiome acquisition.

Key takeaways
  • Q2 revenue decreased significantly as competition from pharmaceutical GLP-1 drugs intensified, impacting sales of the MINDBODY GLP-1 system.
  • Successful launch of two new products from the LoveBiome acquisition, aimed at enhancing consumer engagement and expanding the product portfolio.
  • Continued development of the patent-pending P84 product, which shows promise in the gut health sector and is gaining traction among consumers.
  • Progress on the Shopify partnership is set to modernize e-commerce capabilities, enhancing customer experience and conversion rates.
  • Strategic focus on international market expansion positions the company for growth despite current challenges in the GLP-1 segment.
Full recap

Go deeper on LFVN and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.